NCT01319825

Preventive Treatment of Episodic and Chronic Migraine

Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine.

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: California Medical Clinic for Headache · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is an open label pilot study to determine whether milnacipran can reduce headache frequency in episodic and chronic migraine sufferers.

Detailed description

Patients with episodic migraine with and/or without aura and chronic migraine will be treated with 100 or 200 mg of milnacipran for a total of 4 months including a one month titration phase and a 3 month maintenance phase. Baseline (pre-treatment) and end-of-maintenance phase headache frequencies will be recorded. There is no placebo treatment in this study. In addition to headache frequencies, other parameters being measured include safety and tolerability.

Conditions

• Migraine With Aura
• Migraine Without Aura
• Chronic Migraine

Interventions

Type	Name	Description
DRUG	milnacipran	100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.

Timeline

• Start date: 2011-04-01
• Primary completion: 2012-05-01
• Completion: 2012-07-01
• First posted: 2011-03-22
• Last updated: 2011-03-22

Locations

1 site across 1 country: United States